Inflammation in HIV Infection

a proprietary product derived from rice bran treated with extracts from three mushrooms

arabinoxylan rice bran

Placebo for arabinoxylan rice bran

Rand Schrader Health and Research Clinic

Rice Bran Supplementation in Treated HIV Infection

Anti-Inflammatory Effects of Arabinoxylan Rice Bran Supplementation in Participants With Treated, Suppressed HIV Infection and Inadequate Immune Reconstitution

Michael Dube

Professor of Medicine

University of Southern California

Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).

Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.

Hepatitis C, Chronic

Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.

pegylated IFN

Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.

Biobran

Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).

Ribavirin

Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection

Hosny Salama

Professor

Cairo University

Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan

University of California, Los Angeles

the reduced-osmolarity WHO-ORS without Benefiber.

Cholera

Benefiber

Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS

hemicellulose/upala

Rice Bran Supplementation in Treated HIV Infection

Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults

Najkompletnija baza ljekovitog bilja potpomognuta naukom